Share

August 02, 2016; 87 (5) Views & ReviewsOpen Access

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Clifford R. Jack, David A. Bennett, Kaj Blennow, Maria C. Carrillo, Howard H. Feldman, Giovanni B. Frisoni, Harald Hampel, William J. Jagust, Keith A. Johnson, David S. Knopman, Ronald C. Petersen, Philip Scheltens, Reisa A. Sperling, Bruno Dubois
First published July 1, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002923
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
9122

Share

Article Information

vol. 87 no. 5 539-547
DOI: 
https://doi.org/10.1212/WNL.0000000000002923
PubMed: 
27371494
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received December 16, 2015
  • Accepted in final form March 16, 2016
  • First Published July 1, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Clifford R. Jack Jr, MD,
    2. David A. Bennett, MD,
    3. Kaj Blennow, MD, PhD,
    4. Maria C. Carrillo, PhD,
    5. Howard H. Feldman, MD,
    6. Giovanni B. Frisoni, MD,
    7. Harald Hampel, MD, PhD,
    8. William J. Jagust, MD,
    9. Keith A. Johnson, MD,
    10. David S. Knopman, MD,
    11. Ronald C. Petersen, MD, PhD,
    12. Philip Scheltens, MD, PhD,
    13. Reisa A. Sperling, MD and
    14. Bruno Dubois, MD, PhD
  1. Clifford R. Jack Jr, MD,
    2. Scientific Advisory Boards:

    1. scientific advisory panels: Eli Lily

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health: R01 AG011378, U01 AG024904, RO1 AG041851, R01 AG037551, R01 AG043392, U01 AG006786

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Alexander Family Professorship for Alzheimer's disease Research, Mayo Clinic

    Stock/Stock Options/Board of Directors Compensation:

    1. own stock in Johnson and Johnson Stock/Stock Options, Medical Equipment & Materials: Johnson and Johnson

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. David A. Bennett, MD,
    3. Scientific Advisory Boards:

    1. (1) Vigorous Minds, Scientific Advisory Board (2) Takeda Pharm - Adjudication committee AD4833/TOMM40_301 study

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Editorial Board; (2) Current Alzheimer Research, Editorial Board; (3) Neuroepidemiology, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH: P30AG10161, PI; RF1AG15819, PI; R01AG17917, PI; R01AG36042, PI; U01AG46152, MPI; U01AG46161, MPI; R01AG33678, co-I; R01AG34374, co-I

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Kaj Blennow, MD, PhD,
    4. Scientific Advisory Boards:

    1. Dr Blennow has served at advisory boards for Eli Lilly, IBL International, and Roche Diagnostics.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Fujirebio Europe

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The Research Council, Sweden (project # 14002) and LUA/ALF project, V?stra G?talandsregionen, Sweden (project # ALFGBG-11019)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Torsten S?derberg Foundation at the royal Swedish Academy of Sciences, the Alzheimer Foundation, Sweden, the Stiftelsen f?r Gamla Tj?narinnor, Stockholm, Sweden and Hj?rnfonden, Sweden.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Maria C. Carrillo, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Howard H. Feldman, MD,
    6. Scientific Advisory Boards:

    1. 1. Commercial; Eli Lilly and Co: Advisory Board 2. Commercial; Genentech: Diagnostic Monitoring Committee 4. Commercial Eisai LTD: DSMB 5. Commercial ISIS Pharmaceuticals: Advisory Board 6. Commercial Arena Pharmaceuticals: Advisory Board 7. Commercial Tau Rx: Scientific Advisory Board 8. Merck Pharmaceuticals: Advisory Board Payments from Commercial Organizations to UBC 6. Not for Profit: Tau Consortium: SAB honoraria

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Not for Profit: Tau Consortium Investigator Meetings 2015 (travel expenses) 2. Not for Profit: New York Academy of Sciences and US Against Alzheimer's Disease (travel expenses) 3. Not for Profit: Alzheimer Society of Canada 2015 (travel expenses) 4. Not for Profit: US Alzheimer Association 2015, 2016 (travel expenses) 4. Not for Profit: Brain Canada 2014 (travel expenses)

    Editorial Boards:

    1. NONE

    Patents:

    1. US Serial Number PCT/2007/070008 Detecting and Treating Dementia

    Publishing Royalties:

    1. Royalties from the book Atlas of Alzheimer?s Disease (2007) Informa Health London

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Commercial Arena Pharmaceuticals LTD: 2014

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. Canadian Institutes of Health Research CIHR # 287674 (2013-18)role co Principal Investigator, 2. CIHR Consortium for Neurodegeneration and Aging co Principal Investigator (2014-19), 3. CIHR Canadian Pipeline for AD Therapeutics 2015 Principal Investigator (2015-16)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Giovanni B. Frisoni, MD,
    7. Scientific Advisory Boards:

    1. (1)Lilly (2)BMS (2)Bayer (3)Lundbeck (4)Elan (5)Astra Zeneca (6)Pfizer (7)Taurx (8)Wyeth (9)GE (10)Baxter

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Lilly,speaker. (2)Bayer,speaker. (3)Lundbeck,speaker. (4)Elan,speaker. (5)Astra Zeneca,speaker. (6)Pfizer, speaker.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) IRCCS Fatebenefratelli, Scientific Director since 2013

    Consultancies:

    1. (1) IRCCS SDN Naples, non profit (2) Taurx, commercial

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Wyeth Int.l, (2)Lilly Int.l, (3)Lundbeck Italia (4)GE Int.l (5)Avid/Lilly (6)Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)Alzheimer?s Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Harald Hampel, MD, PhD,
    8. Scientific Advisory Boards:

    1. Commercial entities: 1) Eli Lilly, 2) Avid, 3) Jung Diagnostics, 4) Cytox, 5) Oryzon, 6) Axovant, 7) Anavex, 8) GE, 9) Roche Non-profit entities: OECD, Alzheimer Association, Alzheimer Research Foundation (Paris), Axa Research Fund

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Commercial entities: 1) Roche, 2) Biogen, Non-profit entities: OECD, Alzheimer Association

    Editorial Boards:

    1. Senior Associate Editor of Alzheimer's & Dementia Associate Editor: Journal of Alzheimer's disease, Alzheimer?s & Dementia: Diagnosis, Assessment & Disease Monitoring? (DADM), European Journal of Neurodegeneration, Brain Aging, Functional Neurology; Editorial Board Member: Neuroscience Imaging, Journal of Medical Psychology, World Journal of Neurology, World Journal of Pharmacology, Journal of Diagnostics, European Journal of Neurodegeneration, Journal of Diagnostic Imaging in Therapy.

    Patents:

    1. Several patents, no royalties

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial entities: 1) Eli Lilly, 2) Avid, 3) Jung Diagnostics, 4) Cytox, 5) Oryzon, 6) Axovant, 7) Anavex, 8) GE, 9) Roche Non-profit entities: OECD, Alzheimer Association (Paris), Axa Research Fund

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Pfizer 2) Avid

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Pierre and Marie Curie University, IHU-ICM (Paris)

    Research Support, Foundations and Societies:

    1. Alzheimer Research Foundation (Paris)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. William J. Jagust, MD,
    9. Scientific Advisory Boards:

    1. Genentech 2013-2015 Banner/Genentech DSMB 2013-2016 Banner/Novartis 2014-2016

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate Editor, Frontiers in Human Neuroscience (current). Editorial Board Annals of Neurology, Brain Imaging and Behavior. Alzheimer's Disease and Associated Disorders, Neuroimage: Clinical (current)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant Synarc 2012, 2013, 2014, 2015, 2016 Consultant Genentech 2013, 2014, 2015 Consultant Novartis 2013, 2014, 2015, 2016

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Avid Radiopharmaceuticals F-AV-45-A14 Clinical Evaluation of Florbetapir F-18 (2) GE Healthcare THK5351 pharmacokinetics

    Research Support, Government Entities:

    1. NIH, Principal Investigator on the following grants: AG034570 AG025303 AG044292 NIH Co-Investigator on the following grants: AG012435 AG021028 AG031563 AG019724 AG030048 AG032306 AG024904

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Tau Consortium (Rainwater Foundation) Michael J Fox foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Keith A. Johnson, MD,
    10. Scientific Advisory Boards:

    1. Lundbeck Novartis Abbvie Roche Avid/Lilly Piramal AZTherapies Isis Pharmaceuticals

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. GEHC Biogen Lundbeck

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Piramal Roche Novartis Biogen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. 1) Division of Nuclear Medicine and Molecular Imaging, Department of Imaging, Massachusetts General Hospital, Boston, MA., <5%, 2002-2011; 2) Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital, Boston, MA., <5%, 1993-2011.

    Research Support, Commercial Entities:

    1. Avid/Lilly Biogen

    Research Support, Government Entities:

    1. NIH/NIA: R01 AG027435, PI, 2015 P50 AG00513421, co-I; 2002-date; AG036694 co-PI; 2009-date; R01 AG046396 PI; 2014-date R13 AG042201174210; 2012-date U19AG10483; Co-I; 2012-date U01AG024904; Co-I; 2015-date

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer Association Marr Foundation Fidelity Biosciences Harvard NeuroDiscovery Center

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. David S. Knopman, MD,
    11. Scientific Advisory Boards:

    1. Consultant Bluefield project (frontotemporal demantia); Lundbeck Pharmaceuticals (Sept 2013 ongoing); DIAN study DSMB (Sept 2013 ongoing).

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Lectures, Alzheimer Conference, Seoul Korea, December 2014 (2) Lectures, Behavioral Neurology Conference, Hyderabad, India

    Editorial Boards:

    1. Associate Editor Neurology, ended October 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Tau Rx clinical trial funded by TAURX (site PI) (2) A4 clinical trial partially funded by Lilly (site PI) (3) Biogen Alzheimer Study (site PI)

    Research Support, Government Entities:

    1. NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Ronald C. Petersen, MD, PhD,
    12. Scientific Advisory Boards:

    1. (1) Pfizer, Inc., Chair, Data Monitoring Committee; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Mild Cognitive Impairment,Oxford University Press, 2003

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Roche Incorporated, (2) Merck, (3) Genentech, (4) Biogen, (5) Eli Lilly

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I) Non-financial disclosures: National Advisory Council on Aging, National Institute on Aging

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Philip Scheltens, MD, PhD,
    13. Scientific Advisory Boards:

    1. Advisory boards of: Nutricia Research, GE healthcare, Eli-Lilly, Novartis, Probiodrug, EIP Pharma, Takeda.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. co-editor-in-chief Alz Res & Therapy

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. GE Healthcare Piramal

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer Nederland; sponsor Alzheimer Center, from 2000 onwards Stichting VUmc fonds: sponsor Alzheimer Center from 2005 onwards Innovation Fund: sponsor of Center 2009-2014

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Reisa A. Sperling, MD and
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1)Commercial-Genentech travel 2)Not for Profit-Foundation for NIH- travel 3)Commercial- Otsuka Pharmaceuticals 4)Commercial- Lundbeck

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Personal: 1) Abbvie, commercial 2) Biogen, commercial 3) Genentech, commercial 4) Bracket, commercial 5)Roche, commercial 6) Sanofi, commercial 7) Lundbeck, commercial 8)Avid, commercial 9)Isis Pharmaceuticals, commercial 10)Otsuka Pharmaceuticals, commercial Spouse: 1)Lundbeck, commercial 2) Piramal Healthcare, commercial, 3) Siemens, commercial 4) Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Janssen- investigator-initiated imaging study, 2012-2014. Eli Lilly- clinical trial support 2014-present

    Research Support, Government Entities:

    1. 1) National Institute on Aging R01AG027435, Principal investigator, 2006-2017; 2) National Institute on Aging P01AG036694, principal investigator, 2010-2015; 3) National Institute on Aging P50AG005134, 2009-2014, Project leader; 4) National Institute on Aging U19 AG10483, Project Leader A4 trial, 2012-2017.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. American Health Assistance Foundation, principal investigator, 2010-2014. Alzheimer's Association, co-principal investigator, 2012- 2014.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Bruno Dubois, MD, PhD
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Eli Lilly, Boehringer-Ingelheim

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Pfizer, Fondation Merck Avenir, Amivid

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, Mölndal Hospital, Sahlgrenska University Hospital, Mölndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universités (H.H.), Université Pierre et Marie Curie, Paris; Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle épinière (ICM) (H.H.), Département de Neurologie, Hôpital de la Pitié-Salpétrière, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle épinière, Paris; and Université Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, Hôpital de la Salpêtrière, Paris, France.
  1. Correspondence to Dr. Jack: jack.clifford{at}mayo.edu
View Full Text

Article usage

Article usage: July 2016 to January 2021

AbstractFullPdfSource
Jul 2016132091174Highwire
Aug 20161378427493Highwire
Aug 201603924pmc
Sep 2016244150148Highwire
Sep 2016015183pmc
Oct 2016170116160Highwire
Oct 20160130210pmc
Nov 20161007588Highwire
Nov 20160107111pmc
Dec 2016866387Highwire
Dec 201607142pmc
Jan 2017102189107Highwire
Jan 2017010069pmc
Feb 201711530492Highwire
Feb 2017011350pmc
Mar 2017685172Highwire
Mar 2017010640pmc
Apr 2017606149Highwire
Apr 20175588108pmc
May 2017785770Highwire
May 20174985100pmc
Jun 20175011365Highwire
Jun 2017427077pmc
Jul 20176336480Highwire
Jul 201765103135pmc
Aug 20175629984Highwire
Aug 201761111137pmc
Sep 20177520485Highwire
Sep 201758107132pmc
Oct 20177011091Highwire
Oct 201765123137pmc
Nov 20175116673Highwire
Nov 201766130144pmc
Dec 20172535035Highwire
Jan 20183418384Highwire
Feb 20184122874Highwire
Mar 20182021770Highwire
Apr 20184326798Highwire
Apr 201890165182pmc
May 201842310114Highwire
Jun 20181825952Highwire
Jun 201850141174pmc
Jul 20182426851Highwire
Aug 20181924171Highwire
Aug 201855130155pmc
Sep 201830274108Highwire
Oct 20182222980Highwire
Nov 201882187150Highwire
Dec 20184122993Highwire
Jan 201947221117Highwire
Feb 20193417897Highwire
Mar 201970213146Highwire
Apr 201931257106Highwire
May 201956178125Highwire
Jun 201950143111Highwire
Jul 20194318687Highwire
Aug 20194716687Highwire
Sep 20193714297Highwire
Oct 20194715189Highwire
Nov 201960149113Highwire
Dec 20193615886Highwire
Jan 20203013386Highwire
Feb 20204915394Highwire
Mar 202022272107Highwire
Apr 202035141141Highwire
May 202029149113Highwire
Jun 202025148139Highwire
Jul 20202413797Highwire
Aug 202021156113Highwire
Sep 202068187142Highwire
Oct 202059256175Highwire
Nov 202047203162Highwire
Dec 202050182124Highwire
Jan 202149188160Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me